Boston Scientific hits 52-week high on Q1 beat

seekingalpha04-24

Boston Scientific (NYSE:BSX) shares reached a 52-week high on Wednesday after the medical device maker topped Street forecasts with its Q1 2024 financials and raised its full-year outlook to a level ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2429051468?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/56336385/image_56336385.jpg","is_english":true,"pubTime":"2024-04-24 23:53","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2429051468","market":"us","top_or_hot":-1,"title":"Boston Scientific hits 52-week high on Q1 beat","media":"seekingalpha","content":"<div>\n<p>Boston Scientific (NYSE:BSX) shares reached a 52-week high on Wednesday after the medical device maker topped Street forecasts with its Q1 2024 financials and raised its full-year outlook to a level ...</p>\n\n<a href=\"https://seekingalpha.com/news/4093251-boston-scientific-stock-gains-q1-beat\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boston Scientific hits 52-week high on Q1 beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoston Scientific hits 52-week high on Q1 beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-24 23:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4093251-boston-scientific-stock-gains-q1-beat><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Boston Scientific (NYSE:BSX) shares reached a 52-week high on Wednesday after the medical device maker topped Street forecasts with its Q1 2024 financials and raised its full-year outlook to a level ...</p>\n\n<a href=\"https://seekingalpha.com/news/4093251-boston-scientific-stock-gains-q1-beat\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2087625088.SGD","symbol_name":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","start_time":0,"source_url":"https://seekingalpha.com/news/4093251-boston-scientific-stock-gains-q1-beat","article_id":"2429051468","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/56336385/image_56336385.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429051468","pubTimestamp":1713974003,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Boston Scientific (NYSE:BSX) shares reached a 52-week high on Wednesday after the medical device maker topped Street forecasts with its Q1 2024 financials and raised its full-year outlook to a level a","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BSX":"波士顿科学","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","BK4082":"医疗保健设备","BSX.AU":"BLACKSTONE MINERALS LTD","LU0882574055.USD":"富达全球健康医疗A ACC","BK4588":"碎股","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK7095":"多种金属与采矿","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4581":"高盛持仓","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4504":"桥水持仓","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)"},"translate_title":"波士顿科学在Q1节拍上创下52周新高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1,"BSX.AU":1},"content_text":"Boston Scientific (NYSE:BSX) shares reached a 52-week high on Wednesday after the medical device maker topped Street forecasts with its Q1 2024 financials and raised its full-year outlook to a level above consensus. Marlborough, Massachusetts-based MedTech reported $3.9B in net sales for the quarter, with ~14% YoY growth following a broad-based performance as the company exceeded Wall Street's expectations for every individual business segment. Its cardiology business stood out, with $1.9B in net sales and ~17% YoY growth, beating $1.8B in the consensus, according to Bloomberg forecasts. \"Our exceptional results this quarter were fueled by our talented global team and the strength of our diversified businesses and pipeline,\" CEO Mike Mahoney remarked. Mahoney specifically referred to the initial U.S. launch of the company's Farapulse Pulsed Field Ablation System, which received FDA approval for atrial fibrillation in January, leading to an immediate nationwide rollout. Meanwhile, endoscopy and urology net sales grew ~11% YoY and ~9% YoY to $642M and $513M, exceeding $631.7M and $500.4M in the consensus, respectively. Boston Scientific (BSX) raised its full-year adjusted earnings per share guidance to $2.29–$2.34 from $2.23–$2.27, ahead of the $1.91 projected by analysts. Its Q2 outlook for adj. EPS at $0.57–$0.59 also topped $0.48 in the consensus.  More on Boston Scientific  Boston Scientific Corporation (BSX) Q1 2024 Earnings Call Transcript Boston Scientific Corporation 2024 Q1 - Results - Earnings Call Presentation Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash Boston Scientific Non-GAAP EPS of $0.56 beats by $0.05, revenue of $3.86B beats by $180M Boston Scientific Q1 2024 Earnings Preview","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429051468"}